Anti-T-lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) reduces complications and infection-related mortality compared to post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation from unrelated donors [1]. Although PTCy was associated with fewer cases of acute (Grade II–IV) and chronic GvHD, this did not result in a survival benefit for patients with blood cancer [1]. These initial results from the GRAPPA study were presented by DKMS as a late-breaking abstract at the European Hematology Association (EHA) Congress in Stockholm.